Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review

Tafenoquine is an 8-aminoquinoline anti-malarial drug recently approved as a single-dose (300 mg) therapy for Plasmodium vivax relapse prevention, when co-administered with 3-days of chloroquine or other blood sc...

Source: Malaria Journal - March 14, 2020 Category: Infectious Diseases Authors: Stephan Duparc, Stephan Chalon, Scott Miller, Naomi Richardson and Stephen Toovey Tags: Review Source Type: research